Antibody Therapy for Hematologic Malignancies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 270
Special Issue Editor
Special Issue Information
Dear Colleagues,
We are excited to create this Special Issue dedicated to Antibody Therapy for Hematologic Malignancies, which welcomes both original research and review articles. Since the approval of rituximab for CLL in 1997, therapeutic antibodies have taken a major role in the treatment of this disease and others. Although highly effective therapies such as Bruton tyrosine kinase inhibitors, e.g., ibrutinib and acalabrutinib, are now in common use for diseases such as CLL, efforts to improve the impact of antibody therapy—as single-agent or as part of combination therapy—are ongoing. Antibody therapy is becoming more sophisticated, with the design and engineering of bi- and tri-specific forms, and even with cell-based antibody production strategies. In this Special Issue, we wish to include manuscripts that focus on the usage, mechanisms and future potential of antibody therapy for hematologic malignancies. Collectively, we can showcase this established yet still-developing field that continues to impact treatment.
Dr. Jonathan P. Butchar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematologic malignancies
- leukemia
- lymphoma
- antibody therapy
- immune therapy
- cellular therapy
- combination therapy
- bispecific
- BiTE
- trispecific
- tumor antigens
- Fc receptors
- signaling
- microenvironment
